China Covid Booster

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.

The government today approved the inclusion of an intranasal Covid vaccine in the vaccination programme as a booster dose for adults. The inclusion comes amid a surge in cases in China and some other countries.

Between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity, according to London-based global health intelligence and analytics firm.

China's National Health Commission (NHC) will roll out the second COVID-19 vaccine booster shots for high-risk groups and elderly people over 60 years old, it said in a statement on Wednesday.

China's CanSino Biologics Inc said on Sunday that its recently developed COVID-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.

The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.

Last week, the health ministry urged Indian states to boost surveillance measures for the disease, citing a resurgence in some parts of Asia and Europe. Countries such as China and Italy have seen a recent rise in cases.

Three doses of Sinovac's CoronaVac COVID-19 vaccine do not produce adequate levels of antibodies to fight the Omicron variant of the coronavirus, researchers from Hong Kong said in a statement.

The United States rejected an appeal from the UN health agency on Wednesday for a moratorium on Covid-19 vaccine booster shots, while China tightened overseas travel curbs after recording its highest number of infections in six months.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.

The government today approved the inclusion of an intranasal Covid vaccine in the vaccination programme as a booster dose for adults. The inclusion comes amid a surge in cases in China and some other countries.

Between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity, according to London-based global health intelligence and analytics firm.

China's National Health Commission (NHC) will roll out the second COVID-19 vaccine booster shots for high-risk groups and elderly people over 60 years old, it said in a statement on Wednesday.

China's CanSino Biologics Inc said on Sunday that its recently developed COVID-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.

The prices of Covishield and Covaxin vaccines at private hospitals have been slashed by more than half. This comes a day before the Covid vaccine booster shots become available to all Indian adults.

Last week, the health ministry urged Indian states to boost surveillance measures for the disease, citing a resurgence in some parts of Asia and Europe. Countries such as China and Italy have seen a recent rise in cases.

Three doses of Sinovac's CoronaVac COVID-19 vaccine do not produce adequate levels of antibodies to fight the Omicron variant of the coronavirus, researchers from Hong Kong said in a statement.

The United States rejected an appeal from the UN health agency on Wednesday for a moratorium on Covid-19 vaccine booster shots, while China tightened overseas travel curbs after recording its highest number of infections in six months.